Eloralintide is an investigational weight-loss medicine from Eli Lilly that copies amylin, a fullness hormone your pancreas releases alongside insulin. It is given once a week by injection, and it was known as LY3841136 before it got a name.
Results: strong for a single drug, but still Phase 2. In a 48-week trial of 263 adults without diabetes, average weight loss ranged from 9.5% to 20.1%, against 0.4% on placebo.
The combination is the bigger headline. Paired with tirzepatide (the drug in Zepbound and Mounjaro) in 367 adults with type 2 diabetes, the combination Lilly calls EloraTZP reached up to 23.3% weight loss at 48 weeks, compared with 14.8% for the highest tirzepatide dose alone.
Side effects: nausea and fatigue. Both rose with higher fixed doses and were lower with slower dose increases. Fatigue was common in the highest-dose groups.
Status: not approved anywhere. Eight Phase 3 trials are listed on ClinicalTrials.gov, and the earliest primary completion dates are in early 2028.
This PeptIQ.io guide was updated on November 11, 2026 from PubMed, ClinicalTrials.gov, Eli Lilly and FDA label documents. It contains no dosing information.
Talk to a licensed clinician before starting any weight-loss medicine, including anything sold as eloralintide.
What Is Eloralintide?
Start with the hormone it copies. Amylin is a small peptide hormone that beta cells in the pancreas release together with insulin after you eat. It helps you feel full and slows how fast food leaves the stomach.
Eloralintide is a lab-made, long-acting molecule designed to switch on amylin receptors for a week at a time. Lilly describes it as a "selective amylin receptor agonist" and says its effect on calorie intake is "likely mediated by affecting satiety, or the feeling of fullness."
It is not the first amylin drug. Pramlintide (Symlin) was approved in the US in 2005, but only as an add-on for people with type 1 or type 2 diabetes who already use mealtime insulin. Its label carries a boxed warning: used with insulin, it raises the risk of severe low blood sugar. Pramlintide is taken before meals, several times a day, which is part of why the newer long-acting amylin drugs are getting so much attention.
How It Differs From Cagrilintide and GLP-1 Drugs
Amylin does not have one receptor. It works through a family: the calcitonin receptor on its own, and that same receptor paired with partner proteins to form amylin receptors (AMY1, AMY2, AMY3). Which of these a drug hits shapes what it does.
PeptIQ.io / Eloralintide / 01
Two fullness signals, three molecules.
Amylin and GLP-1 both curb appetite, through different receptors. Eloralintide is the amylin drug designed to be picky about which receptor it switches on.
Lilly · selective amylin agonist
Eloralintide
Built to favor the AMY1 amylin receptor
In lab tests, about 12x more active at AMY1 than at the calcitonin receptor
Caused less taste aversion than cagrilintide in lean rats
Novo Nordisk · in CagriSema
Cagrilintide
Long-acting amylin analog
Described as non-selective: hits amylin and calcitonin receptors
Paired with semaglutide in CagriSema
Lilly · Zepbound, Mounjaro
Tirzepatide
Not an amylin drug at all
Acts on GIP and GLP-1 receptors
The partner drug in EloraTZP
The bet: selectivity could mean similar weight loss with fewer side effects. Phase 3 has to prove that in people.
Evidence, not marketing.Nov 2026
Sources: Briere et al., Mol Metab 2025 (PubMed 41109426), receptor selectivity and rat taste-avoidance data; Eli Lilly EloraTZP release, Sept 30, 2026. Selectivity figures are from cell assays; rat findings may not carry over to people.
Eloralintide is built to be selective. In Lilly's lab work, it activated the human AMY1 receptor about 12 times more readily than the calcitonin receptor, and about 11 times more readily than AMY3. Novo Nordisk's cagrilintide — the amylin half of CagriSema — is described in the same paper as a non-selective amylin agonist.
Why would selectivity matter? Lilly's hypothesis is tolerability. In lean rats, eloralintide caused significantly less "conditioned taste avoidance" than cagrilintide — a lab measure of how much an animal learns to avoid a flavor it associates with feeling sick. In diet-induced obese rats, it reduced food intake and body weight, mainly through fat loss. Those are animal findings. Whether selectivity translates into fewer side effects in people is what the Phase 3 program has to show.
GLP-1 drugs work through a different hormone. Semaglutide and tirzepatide act on GLP-1 (and, for tirzepatide, GIP) receptors. GLP-1 and amylin both curb appetite and slow the stomach, but through separate receptors. That is the logic behind pairing them: two fullness signals instead of one.
What the Evidence Actually Shows
Every human study of eloralintide so far was funded by Lilly, and most authors are Lilly employees. That is normal for a drug at this stage, but it is worth knowing. Here is what has been published, in order.
PeptIQ.io / Eloralintide / 02
Where the evidence stands.
Read it from the top. The rung that would get eloralintide approved, Phase 3, has no results yet.
Phase 3
Eight trials, more than 11,000 planned participants. No results yet; earliest primary completion early 2028.
Pending
Phase 2b with tirzepatide
367 adults with type 2 diabetes, 48 weeks. Combination reached up to 23.3% weight loss. Presented at EASD, Sept 2026; not on PubMed as of Nov 11.
Meeting data
Phase 2
263 adults without diabetes, 48 weeks, placebo-controlled. 9.5% to 20.1% average weight loss. Published in The Lancet.
Strongest
Phase 1
48 healthy adults given single doses, then 100 adults over 12 weeks. Safety, drug levels and early weight change.
Early
Lab and animal
Receptor selectivity in cells; lower food intake and fat loss in obese rats; drug levels in rats and monkeys.
Foundation
Evidence, not marketing.Nov 2026
Sources: Billings et al., Lancet 2025 (PubMed 41207310); Bhattachar et al., Diabetes Obes Metab 2026 (PubMed 41559929); Briere et al., Mol Metab 2025 (PubMed 41109426); Eli Lilly release, Sept 30, 2026 (NCT06603571); ClinicalTrials.gov, checked Nov 11, 2026. All trials were funded by Lilly.
Phase 1, single doses (48 healthy adults). Published in Molecular Metabolism in 2025, this trial gave one injection at a range of doses. Nine participants on eloralintide reported 16 adverse events, 15 of them mild. Two people reported four stomach-related events. Four weeks after a single injection, the two highest dose groups had lost 2.5% and 4.4% of body weight, against a 0.6% gain on placebo. The authors said its pharmacokinetic profile supports once-weekly use.
Phase 1, 12 weeks of weekly doses (100 adults with obesity or overweight). Published in Diabetes, Obesity and Metabolism in 2026. People started directly at their assigned dose, with no gradual increase. The most common side effects were decreased appetite (19%), headache (12%), fatigue (11%) and COVID-19 (11%). Diarrhea (10%), nausea (8%) and vomiting (4%) were described as infrequent. Weight loss at 12 weeks ranged from 2.6% to 11.3% across dose groups.
Phase 2, 48 weeks (263 adults without diabetes). This is the main trial, published in The Lancet in November 2025 (NCT06230523). Participants had a BMI of 30 or higher, or 27 or higher with a weight-related condition, and no type 2 diabetes. Their average starting weight was 109.1 kg and 78% were women. They were randomized to placebo, one of four fixed doses, or one of two schedules that stepped the dose up over time.
Average weight loss ranged from 9.5% in the lowest-dose group to 20.1% in the highest, against 0.4% on placebo.
Lilly also reported improvements in waist circumference, blood pressure, lipids, blood sugar control and inflammation markers.
These figures use the efficacy estimand: what would have happened had everyone stayed on treatment. Real-world results are usually lower, because some people stop.
Phase 2b with tirzepatide, 48 weeks (367 adults with type 2 diabetes). Presented at the EASD meeting in Milan on September 30, 2026 (NCT06603571). Participants averaged 105.4 kg with an A1C of 8.1%, and the two drugs were given as separate injections.
Eloralintide alone: up to 12.3% weight loss and up to a 1.4-point A1C drop.
Tirzepatide alone, highest dose: 14.8% weight loss and a 2.4-point A1C drop.
EloraTZP: 13.2% to 23.3% weight loss and up to a 2.9-point A1C drop, depending on the dose pairing.
Placebo: 3.0% weight loss and a 0.3-point A1C drop.
Two things are worth noticing. Weight loss was smaller in this type 2 diabetes trial — eloralintide alone reached 12.3% here versus 20.1% in people without diabetes, though the two trials differed in design and are not a direct comparison. And the combination beat the highest dose of tirzepatide by a wide margin, which is why Lilly is moving it straight into Phase 3.
PeptIQ.io / Eloralintide / 03
Average weight loss at 48 weeks.
Two different trials in two different populations. Compare bars within a panel, not across them.
Phase 2 · adults without diabetes
Eloralintide, highest-dose group20.1%
Eloralintide, lowest-dose group9.5%
Placebo0.4%
Phase 2b · adults with type 2 diabetes
EloraTZP, highest pairing23.3%
Tirzepatide alone, highest dose14.8%
Eloralintide alone, best group12.3%
Placebo3.0%
The trade-off: 10.8% to 27.0% of people on EloraTZP stopped because of side effects, against 2.9% on tirzepatide alone.
Evidence, not marketing.Nov 2026
Efficacy estimand: results had everyone stayed on treatment. Sources: Billings et al., Lancet 2025 (PubMed 41207310) and Eli Lilly release, Nov 6, 2025 (NCT06230523); Eli Lilly release, Sept 30, 2026 (NCT06603571). Not a dosing guide.
Independent analysis. A 2026 network meta-analysis in Endocrinology, Diabetes & Metabolism pooled six trials of long-acting amylin drugs (4,642 people). High-dose eloralintide ranked second for weight loss, at about 18% more than placebo, behind subcutaneous amycretin and ahead of high-dose CagriSema. The authors called the data "sparse" and "low-certainty" and said the findings "are preliminary and require confirmation in larger trials."
Side Effects: What the Trials Reported
The side-effect picture is consistent across the trials, and it is mostly about how fast the dose goes up.
Nausea. In Phase 2 it ranged from 11% in the lowest-dose group to 64% in one high fixed-dose group, against 14% on placebo. The groups that stepped up gradually had lower rates than those started directly at a high dose.
Fatigue. It ranged from 0% at the lowest dose to 43–46% in the highest-dose groups, against 12% on placebo. Fatigue is one of the clearest signals for this drug, and it is worth raising with a clinician.
Low-dose groups looked like placebo. Lilly reported that gastrointestinal and fatigue rates in the two lowest-dose groups were similar to placebo.
The combination is harder to tolerate. In the EloraTZP trial, stomach-related side effects were more common in the combination groups and happened mostly during dose increases. Between 10.8% and 27.0% of people on EloraTZP stopped treatment because of side effects, against up to 10.8% on eloralintide alone and 2.9% on tirzepatide alone. (Lilly reported 16.7% for placebo in that trial.) Lilly says Phase 3 will use an "optimized escalation schedule."
What is not known yet: anything about rare side effects, long-term safety beyond 48 weeks, or outcomes like heart attacks and strokes. Trials with a few hundred people cannot detect uncommon problems. That is what the Phase 3 program, with more than 11,000 planned participants, is for.
The 2026 Phase 3 Program
Lilly runs two Phase 3 programs: ENLIGHTEN for eloralintide on its own, and AMPLIFY for the EloraTZP co-formulation, a single injection containing both drugs.
PeptIQ.io / Eloralintide / 04
Eight Phase 3 trials, none finished.
Sorted by estimated primary completion. ENLIGHTEN tests eloralintide alone; AMPLIFY tests the EloraTZP single-injection combination.
ENLIGHTEN-2
Jan 2028
Type 2 diabetes
1,035 people
Recruiting
ENLIGHTEN-1
Mar 2028
Obesity, no diabetes
1,980 people
Recruiting
ENLIGHTEN-3
Mar 2028
Sleep apnea
800 people
Recruiting
ENLIGHTEN-4
Mar 2028
Knee osteoarthritis pain
900 people
Recruiting
ENLIGHTEN-6
Jun 2028
Add-on to a weekly incretin
900 people
Recruiting
AMPLIFY-2
Oct 2029
EloraTZP, type 2 diabetes
1,000 people
Recruiting
AMPLIFY-1
Oct 2029
EloraTZP vs each drug alone
2,115 people
Not yet recruiting
ENLIGHTEN-10
Nov 2029
Diabetes + cardiovascular risk
3,000 people
Not yet recruiting
Evidence, not marketing.Nov 2026
Source: ClinicalTrials.gov registry entries NCT07282600, NCT07321886, NCT07369011, NCT07353931, NCT07392190, NCT07881458, NCT07881432, NCT07900633, checked November 11, 2026. Enrollment and dates are sponsor estimates and can change.
Listed on ClinicalTrials.gov as of November 11, 2026:
ENLIGHTEN-1 (NCT07321886): about 1,980 adults with obesity or overweight and no type 2 diabetes. Recruiting since February 2026. Primary result at week 64, with a two-year extension for people with prediabetes.
ENLIGHTEN-2 (NCT07282600): about 1,035 adults with type 2 diabetes. Recruiting since December 2025.
ENLIGHTEN-3 (NCT07369011): about 800 adults with obstructive sleep apnea.
ENLIGHTEN-4 (NCT07353931): about 900 adults with knee osteoarthritis pain.
ENLIGHTEN-6 (NCT07392190): about 900 adults who still have obesity while already on a weekly incretin drug, testing eloralintide as an add-on.
ENLIGHTEN-10 (NCT07900633): about 3,000 adults with type 2 diabetes and raised cardiovascular risk. Not yet recruiting; planned start December 2026.
AMPLIFY-1 (NCT07881432): about 2,115 adults without type 2 diabetes, comparing EloraTZP with tirzepatide, eloralintide and placebo at 100 weeks. Not yet recruiting.
AMPLIFY-2 (NCT07881458): about 1,000 adults with type 2 diabetes. Recruiting since October 2026.
The earliest primary completion dates listed are January to March 2028, and the AMPLIFY trials run to late 2029. Approval decisions come after results are analyzed and filed, so eloralintide should not be expected in pharmacies before then.
If you want access before approval, the legitimate route is a trial. ClinicalTrials.gov lists recruiting sites and eligibility rules for each study above.
Is Eloralintide FDA Approved or Legal to Buy?
No, it is not approved by the FDA or any other regulator. Lilly calls both eloralintide and EloraTZP "investigational." The only approved amylin drug in the US remains pramlintide, for people with diabetes on mealtime insulin.
It is not part of the 2026 compounding policy. The HHS enforcement-discretion policy published on October 30, 2026 names six peptides in Appendix A — BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Eloralintide is not one of them, so that policy gives pharmacies no cover to compound it.
Products sold online as "eloralintide" are not the trial drug. Lilly is the only developer, and it does not sell eloralintide. Anything marketed under that name is a research-use product of unknown identity, purity and strength, made without the controls that apply to a medicine. If someone is offering to prescribe it, ask what exactly you would be receiving and from whom. Meds.you, the parent of a group of telehealth brands, says its brands use "real providers" and "named pharmacies"; whoever you use, those are the two things to confirm in writing. Our guide on how to vet a peptide source covers the documents to request.
Questions to Ask a Clinician
Am I a candidate for an approved option now — semaglutide, tirzepatide or another — rather than waiting for eloralintide?
If I am already on a GLP-1 or tirzepatide and have plateaued, is a trial like ENLIGHTEN-6 worth looking into?
How would you watch for fatigue, and how would we tell it apart from eating less?
I take insulin or a sulfonylurea. How would an amylin drug change my risk of low blood sugar?
What would make you advise me to stop?
How PeptIQ.io Helps
PeptIQ.io's Peptide Claim Auditor takes a link to an Instagram, TikTok, X or Reddit post and checks each claim in it against published research. It is useful on posts quoting the 20% or 23% figures without saying they come from Phase 2 trials, or without saying which population they apply to. The guide to reading a certificate of analysis explains what a lab report does and does not prove. If you and your clinician start an approved weight-loss medicine, the PeptIQ app keeps doses, weight, labs and symptoms on one timeline you can share, and PeptIQ AI answers questions against your own log rather than a forum thread.
Talk to a Licensed Clinician
Talk to a licensed clinician before starting any weight-loss medicine. Eloralintide looks promising, but it has 48-week data from a few hundred people, not the multi-year safety record of the drugs already approved. If you are interested in it specifically, ask your clinician about trial eligibility. If you are already using a product sold under that name, tell your clinician, and bring the product and its label.
Frequently Asked Questions
Q: What is eloralintide?
A: Eloralintide, formerly LY3841136, is an investigational once-weekly injectable medicine from Eli Lilly that activates amylin receptors. Amylin is a fullness hormone released with insulin after meals. Eloralintide is being studied for obesity and for obesity with type 2 diabetes.
Q: How much weight did people lose on eloralintide?
A: In the 48-week Phase 2 trial of 263 adults without diabetes, average weight loss ranged from 9.5% to 20.1% across dose groups, against 0.4% on placebo. In adults with type 2 diabetes, eloralintide alone reached up to 12.3%. These are efficacy-estimand results, which assume everyone stayed on treatment.
Q: What are the side effects of eloralintide?
A: The most common were nausea and fatigue, both more frequent at higher fixed doses and less frequent when the dose was increased gradually. In Phase 2, nausea reached 64% in one high-dose group and fatigue reached 46%, against 14% and 12% on placebo. Rates in the lowest-dose groups were similar to placebo.
Q: What is EloraTZP?
A: EloraTZP is Lilly's combination of eloralintide and tirzepatide. In a 48-week Phase 2b trial of 367 adults with obesity and type 2 diabetes, it produced up to 23.3% weight loss and up to a 2.9-point A1C drop, against 14.8% and 2.4 points for the highest tirzepatide dose alone. Between 10.8% and 27.0% stopped because of side effects. A single-injection version is entering Phase 3 as AMPLIFY-1 and AMPLIFY-2.
Q: Is eloralintide FDA approved?
A: No. It is in Phase 3 trials, and the earliest listed primary completion dates are in early 2028. The only approved amylin drug in the US is pramlintide (Symlin), for people with diabetes who use mealtime insulin.
Q: How is eloralintide different from cagrilintide?
A: Both are long-acting amylin drugs. Eloralintide is designed to be selective for the AMY1 receptor, activating it about 12 times more readily than the calcitonin receptor in lab tests. Cagrilintide, the amylin half of Novo Nordisk's CagriSema, is non-selective. In rats, eloralintide caused less taste aversion than cagrilintide. Whether that means better tolerability in people is not yet known.
Q: Can I get eloralintide now?
A: Only through a clinical trial. Lilly does not sell it, and it is not on the HHS list of peptides pharmacies may compound. Products sold online under the name are not the trial drug and are not tested to medicine standards.
Billings LK, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2025;406:2631-2643. PubMed 41207310
Briere DA, et al. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: from discovery to clinical proof of concept. Mol Metab. 2025. PubMed 41109426
Bhattachar S, et al. Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. Diabetes Obes Metab. 2026. PubMed 41559929
Kamrul-Hasan ABM, et al. Novel amylin-based therapies for weight management in adults with overweight or obesity without diabetes: a network meta-analysis. Endocrinol Diabetes Metab. 2026. PubMed 42175595
This article is educational content from PeptIQ.io. It is not medical advice. Talk with a licensed clinician before starting, stopping, or changing any peptide, medication, or injection practice.
For clinics: running peptide or GLP-1 programs for patients? See PeptIQ.io for providers: protocol templates, a patient app, and adherence tracking in one console.